Alpha DaRT + Keytruda Achieves 100% Response Rate in Head and Neck Cancer Trial
DRTS has more than doubled off its 52-week low of $2.87.
Summary
Alpha Tau's Alpha DaRT combined with Merck's Keytruda produced a 100% objective response rate in nine evaluable elderly patients with advanced head and neck cancer, far exceeding the 19% benchmark for Keytruda alone. Median overall survival reached 18.2 months versus 12.3 months historically, with no serious Alpha DaRT-related side effects. The trial met its pre-specified success threshold, stopping enrollment early. This follows a string of positive data across pancreatic cancer, glioblastoma, and now head and neck, building momentum for regulatory discussions. The stock is trading near its 52-week high, reflecting growing confidence in the platform. Next catalyst: FDA feedback on the combination approach and potential pivotal trial design.
At the time of this announcement, DRTS was trading at $14.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.87 to $14.11. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.